Pipeline Insight: Multiple Sclerosis - The oral revolutionPharmaceutical Business Review - USA... (FTY720) goes some way to meet these needs and represents the most highly anticipated pipeline drug since the initial launch of Tysabri in 2004. ...See all stories on this topic